68 posts
Epithalon vs Vilon: Which Is Right for You?
Comparing Epithalon and Vilon: both have distinct mechanisms, FDA status, and use cases. Read the sections below to decide which may be right for you.
Oct 2, 2026GHK-Cu vs BPC-157: Which Is Right for You?
GHK-Cu is compoundable for topical use only (Category 1); it is a legal option for skin and wound support. BPC-157 is prohibited for compounding and has no FDA approval—it is not a legal option in the US. For legal tissue and skin support, GHK-Cu (topical) is the only one you can use.
Oct 2, 2026Ipamorelin vs GHRP-2: Which Is Right for You?
Ipamorelin is prohibited for compounding with no pathway. GHRP-2 has complex status—Category 1 on 503B for non-injectable, non-nasal routes only; injectable use is not permitted. For legal injectable GH support, neither is a clear option; sermorelin is the compoundable choice.
Oct 2, 2026PT-141 vs Melanotan II: Which Is Right for You?
PT-141 (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women and is safe when used as directed. Melanotan II is not FDA-approved, has no legal pathway, and carries significant safety concerns including nausea, flushing, and potential melanoma risk. Do not use Melanot
Oct 2, 2026Retatrutide vs Tirzepatide: Which Is Right for You?
Tirzepatide is the practical choice today: it is a dual GIP/GLP-1 agonist that is FDA-approved (Mounjaro for type 2 diabetes, Zepbound for obesity) and available by prescription now. Retatrutide is a triple GLP-1/GIP/glucagon agonist that produced higher weight loss in its Phase 2 trials (~24% at 48
Oct 2, 2026Semaglutide vs Tirzepatide: Which Is Right for You?
Tirzepatide is a dual GIP/GLP-1 agonist and often produces slightly greater weight loss than semaglutide (GLP-1 only) in trials. Both are FDA-approved for type 2 diabetes and obesity. Choice depends on access, cost, and tolerability—many patients do very well on either.
Oct 2, 2026Semax vs Selank: Which Is Right for You?
Semax and Selank are both Russian-origin peptides with moderate evidence from Russian studies. Neither is FDA-approved in the US; Semax has no clear compounding pathway, and Selank's Category 2 nomination was withdrawn. Both are used for cognitive and mood support abroad but are not legal, approved
Oct 2, 2026Sermorelin vs CJC-1295 / Ipamorelin: Which Is Right for You?
Sermorelin is legal to compound (Category 1) and was previously FDA-approved; it is a safe, legal option for growth hormone support. CJC-1295/Ipamorelin combination is not legally compoundable—both components are prohibited—and CJC-1295 has been flagged by the FDA for cardiac risks. For legal GH sup
Oct 2, 2026Thymosin Alpha-1 vs TB-500: Which Is Right for You?
Thymosin alpha-1 (Zadaxin) is approved in many countries for immune modulation but is not FDA-approved in the US; its 503A Category 2 nomination was withdrawn. TB-500 (thymosin beta-4) is prohibited for compounding and is WADA prohibited. Neither is a straightforward legal option in the US for human
Oct 2, 2026Semaglutide vs Liraglutide: Which Is Right for You?
Semaglutide and liraglutide are both FDA-approved GLP-1 agonists for diabetes and weight loss. Semaglutide is usually given once weekly (or daily oral with Rybelsus) and tends to produce greater weight loss in trials; liraglutide is daily injection and remains a proven, effective option.
Oct 2, 2026Industry, Market and Research Developments
The peptide market moved fast between 2024 and 2026: GLP-1 demand reshaped supply, several vendors shut down, and manufacturers invested in new synthesis and purification capacity. This chapter collects those developments.
Oct 2, 2026How to Choose a Peptide Therapy Clinic
Provider quality varies enormously in this field, and the differences that matter — sourcing, testing, licensing, screening — are rarely visible on a clinic's website. This chapter is a vetting checklist.
Oct 2, 2026